Ulcer News and Research

RSS

Twenty-five million Americans suffer from ulcers. An ulcer is a sore or hole in the lining of the stomach or duodenum (the first part of the small intestine). People of any age can get an ulcer and women are affected just as often as men.

Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that nine out of ten ulcers are caused by H. pylori. Medicines that reduce stomach acid may make you feel better, but your ulcer may come back. Here's the good news: Since most ulcers are caused by this bacterial infection, they can be cured with the right antibiotics.

Advanced Biohealing announces growth strategy to expand its product line

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative medicine company.

24 Sep 2009

National Institute for Health Research funds for wound care research

The University of York's Department of Health Sciences and NHS Leeds Community Healthcare have been awarded a £1.75m grant from the National Institute for Health Research to carry out a study into complex wounds.

17 Sep 2009

Clinical trial focuses on healing diabetic foot ulcers with stem cells

Fortis Healthcare, one of India's leading private hospital groups, has announced it will broaden inclusion criteria for its upcoming diabetic foot clinical trial. The study will use stem cells derived from peripheral blood to treat critical limb ischemia (diabetic foot).

17 Sep 2009

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved its New Drug Application for Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% as a treatment for acute herpetic keratitis (dendritic ulcers). The FDA granted orphan drug designation to Zirgan for this indication in April 2007.

17 Sep 2009

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

A study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned, according to Ozonics International, LLC, a veteran-owned biotechnology company engaged in the research and development of ozone-based medical therapies.

15 Sep 2009

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

A popular stomach-acid reducer used to prevent stress ulcers in critically ill patients needing breathing machine support increases the risk of those patients contracting pneumonia threefold, according to researchers at Wake Forest University School of Medicine.

15 Sep 2009

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Published today, as an original investigation, in the peer-reviewed Journal of Clinical Oncology, are statistically significant Phase II clinical results of The GI Company's lead clinical compound, rhITF (recombinant human Intestinal Trefoil Factor) oral spray. The article is titled, "A Phase II, Randomized, Double-blind, Placebo-Controlled Study of rhITF Oral Spray for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy."

10 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

New technique for tumor therapy under study

In the scientific journal PLoS ONE, Sara Bartels and Siegfried Weiss of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany now show how the bacteria migrate into tumours. A messenger substance from the immune system is the door opener: It makes blood vessels in the cancerous tissue permeable; enabling the bacteria to conquer and destroy the tumour.

9 Sep 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Cardium Therapeutics (NYSE Amex: CXM) today announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.

26 Aug 2009

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg.

25 Aug 2009

Thomson Reuters to supply real-time clinical surveillance solution to Bryanlgh Health System

BryanLGH Health System has selected Clinical Xpert CareFocus from Thomson Reuters to play an integral role in its ongoing efforts to improve clinical quality and patient safety.

24 Aug 2009

Peptic ulcer bacterium alters the body's defence system

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden. The discovery may lead to new treatments against the common peptic ulcer bacterium.

30 Jun 2009

New discovery about mycobacteria – implications for tuberculosis research

A close relative of the microorganism that causes tuberculosis in humans has been found to form spores. This is a sensational finding because researchers have long been convinced that these kinds of bacteria - the mycobacteria - were incapable of forming spores.

9 Jun 2009

Diabetes-related amputations can be reduced

Using fenofibrate to lower blood fats in people with diabetes reduces the risk of a first diabetes-related amputation by 36 per cent. This is among the conclusions of the FIELD study, reported in an article in this week's diabetes special issue of The Lancet.

27 May 2009

Amino acid glutamine show promise in treating stomach ulcers

Nearly 20 years ago, it was discovered that bacteria known as Helicobacter pylori were responsible for stomach ulcers. Since then, antibiotics have become the primary therapy used to combat the H. pylori infection, which affects approximately six percent of the world population and is also a primary cause of stomach cancer. But today the bacteria is growing increasingly resistant to antibiotics.

17 May 2009

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

The drug acyclovir, which suppresses herpes simplex virus-2, does not reduce the risk of HIV transmission when taken by HIV-positive people who also have herpes, according to a study conducted by researchers at the University of Washington, United Press International reports.

14 May 2009

Ulcer News and Research

Advanced Biohealing announces growth strategy to expand its product line

National Institute for Health Research funds for wound care research

Clinical trial focuses on healing diabetic foot ulcers with stem cells

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

Risk for patients contracting pneumonia increases threefold when treated with pantoprazole: Study

GI Company's Phase II study demonstrates safety of rhITF oral spray formulation

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

New technique for tumor therapy under study

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

FDA issues final approval for manufacturing and marketing Ranbaxy's Glycopyrrolate tablets

Thomson Reuters to supply real-time clinical surveillance solution to Bryanlgh Health System

Peptic ulcer bacterium alters the body's defence system

New discovery about mycobacteria – implications for tuberculosis research

Diabetes-related amputations can be reduced

Amino acid glutamine show promise in treating stomach ulcers

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News